Zealand Financial Statements From 2010 to 2024
| ZLDPF Stock | USD 99.52 4.53 4.35% |
Check Zealand Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zealand Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Zealand financial statements analysis is a perfect complement when working with Zealand Pharma Valuation or Volatility modules.
Zealand |
Zealand Pharma AS Company Shares Owned By Insiders Analysis
Zealand Pharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Zealand Pharma Shares Owned By Insiders | 0.07 % |
Most of Zealand Pharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zealand Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 0.07% of Zealand Pharma AS are shares owned by insiders. This is 99.54% lower than that of the Healthcare sector and 99.51% lower than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is 99.31% higher than that of the company.
Zealand Pharma AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zealand Pharma's current stock value. Our valuation model uses many indicators to compare Zealand Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zealand Pharma competition to find correlations between indicators driving Zealand Pharma's intrinsic value. More Info.Zealand Pharma AS is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zealand Pharma's earnings, one of the primary drivers of an investment's value.About Zealand Pharma Financial Statements
Zealand Pharma stakeholders use historical fundamental indicators, such as Zealand Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Zealand Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Zealand Pharma's assets and liabilities are reflected in the revenues and expenses on Zealand Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Zealand Pharma AS. Please read more on our technical analysis and fundamental analysis pages.
Zealand Pharma AS, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 237 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Zealand Pink Sheet
Zealand Pharma financial ratios help investors to determine whether Zealand Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.